Chemed

Q2 FY2026 EarningsQ2 2026 revenue increased 8.8% YoY to $673.3M, with Adjusted Diluted EPS rising 41.9% to $6.06. VITAS net revenue grew 11.9% YoY to $443.3M, supported by a 6.1% increase in ADC and significantly lower Medicare Cap accruals ($0.5M vs. $16.4M). Roto-Rooter revenue grew 3.3% YoY to $229.9M, though Adjusted EBITDA remained flat. Management raised FY2026 Adjusted EPS guidance to $25.00-$25.75 due to VITAS outperformance and share repurchases.